Document is current
Any future updates will be listed below
-
Authors
Jansche, Rebecca
Heitmeir, Benedikt
Faust, Ulrike
Pospiech, Helmut https://orcid.org/0000-0002-5255-0747
Sutter, Christian
Albig, Christian https://orcid.org/0000-0002-8320-5081
Hennig, Finja https://orcid.org/0000-0003-1717-9820
Janni, Wolfgang
Schmutzler, Rita
Hauke, Jan
Joerger, Andreas C. https://orcid.org/0000-0002-1232-0138
Wiesmüller, Lisa https://orcid.org/0000-0002-2397-5041
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (Priority Program ‘Translational Oncology’, project HerediVar´, 70114178)
Deutsche Krebshilfe (Priority Program ‘Translational Oncology’, project HerediVar´, 70114178)
Deutsche Krebshilfe (Priority Program ‘Translational Oncology’, project HerediVar, 70114178)
Deutsche Krebshilfe (`TACTIC´, project number 70115201)
Else Kröner Fresenius Foundation and Medical Faculty, Ulm University, for clinician scientist program
Structural Genomics Consortium (SGC), a registered charity
- License Information
-
More Information
Article History
Received: 22 September 2025
Revised: 15 December 2025
Accepted: 30 January 2026
First Online: 28 February 2026
Competing interests
: JH received support from the AGO study group (AGO Research GmbH) and a honorarium from Astra Zeneca for his scientific presentation in 2024. All the other authors declare no competing financial interests in relation to the work described.
: All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the ethics committee of the University Clinic Cologne, Germany (approval/registration number: 19-1360_4 7 “HerediCaRe”). Informed consent was obtained from all participants included in the study.
